Literature DB >> 11223322

Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data.

T A Trikalinos1, J P Ioannidis.   

Abstract

We developed and evaluated methods for the analysis and interpretation of the baseline risk heterogeneity in meta-analysis of individual patient data (MIPD) based on information on predictive factors. We used data from a typical MIPD of eight clinical trials (1792 patients, 2947 years of follow-up) on the efficacy of high-dose acyclovir in human immunodeficiency virus infection. Cox models with four predictive factors (age, disease state, CD4 cell count and hemoglobin levels) were used to estimate predicted individual hazards both for single trials and for various MIPD modeling methods (simple pooling, adjusted for study, stratified per study, fixed and random effects for predictors). For each study and for each method of MIPD synthesis, we estimated the odds ratio for death in the upper versus the lower quartile of predicted risk (Extreme Quartile Odds Ratio, EQuOR) and the respective rate ratio (Extreme Quartile Rate Ratio, EQuRR). Only the CD4 cell count showed a significantly heterogeneous predictive effect across the eight studies (P =.024). The EQuOR of single studies ranged from 3.5 (little heterogeneity) to 24 (intermediate heterogeneity), substantially lower than the EQuOR of the MIPD (167 to 275, depending on the model used). The EQuRR values ranged from 3.5 to 77 for single studies and from 77 to 116 for the various MIPD models. Predictive modeling can be a major strength of MIPD, when performed and interpreted with standardized approaches. All models consistently show that MIPD may be a study design with extreme heterogeneity of patient baseline risk.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11223322     DOI: 10.1016/s0895-4356(00)00311-5

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  13 in total

1.  Meta-analysis in medical research.

Authors:  A B Haidich
Journal:  Hippokratia       Date:  2010-12       Impact factor: 0.471

2.  Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data.

Authors:  C Cammà; S Bruno; F Schepis; O Lo Iacono; P Andreone; A G Gramenzi; A Mangia; A Andriulli; M Puoti; A Spadaro; M Freni; V Di Marco; L Cino; G Saracco; A Chiesa; A Crosignani; N Caporaso; F Morisco; M G Rumi; A Craxì
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

Review 3.  The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials.

Authors:  Alawi A Alsheikh-Ali; Richard H Karas
Journal:  Curr Atheroscler Rep       Date:  2009-03       Impact factor: 5.113

4.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration.

Authors:  David M Kent; David van Klaveren; Jessica K Paulus; Ralph D'Agostino; Steve Goodman; Rodney Hayward; John P A Ioannidis; Bray Patrick-Lake; Sally Morton; Michael Pencina; Gowri Raman; Joseph S Ross; Harry P Selker; Ravi Varadhan; Andrew Vickers; John B Wong; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2019-11-12       Impact factor: 25.391

5.  Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal.

Authors:  David M Kent; Peter M Rothwell; John P A Ioannidis; Doug G Altman; Rodney A Hayward
Journal:  Trials       Date:  2010-08-12       Impact factor: 2.279

6.  The strengths and limitations of meta-analyses based on aggregate data.

Authors:  Gary H Lyman; Nicole M Kuderer
Journal:  BMC Med Res Methodol       Date:  2005-04-25       Impact factor: 4.615

7.  Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.

Authors:  Qiuyan Yu; Zhenli Zhu; Yan Liu; Jun Zhang; Ke Li
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

8.  Consensus-based recommendations for investigating clinical heterogeneity in systematic reviews.

Authors:  Joel J Gagnier; Hal Morgenstern; Doug G Altman; Jesse Berlin; Stephanie Chang; Peter McCulloch; Xin Sun; David Moher
Journal:  BMC Med Res Methodol       Date:  2013-08-30       Impact factor: 4.615

Review 9.  Investigating clinical heterogeneity in systematic reviews: a methodologic review of guidance in the literature.

Authors:  Joel J Gagnier; David Moher; Heather Boon; Joseph Beyene; Claire Bombardier
Journal:  BMC Med Res Methodol       Date:  2012-07-30       Impact factor: 4.615

10.  Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysis.

Authors:  Z Zhu; J Zhang; Y Liu; M Chen; P Guo; K Li
Journal:  Br J Cancer       Date:  2014-04-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.